Matinas Biopharma (NYSEAMERICAN:MTNB) Inc. is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.
The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections. Unlike standard intravenous amphotericin B, MAT2203 is formulated for once‐daily oral dosing and is intended to offer a lower toxicity profile. Matinas is also advancing MAT9001, an intravenous formulation of omega‐3 fatty acids for the management of severe hypertriglyceridemia, and MAT2501, an intravenous lipid‐based formulation of gentamicin for multidrug‐resistant bacterial infections.
Founded in 2012 and headquartered in Bedminster, New Jersey, Matinas Biopharma has designed its pipeline to address high‐unmet‐need areas in infectious disease and metabolic disorders. The company’s development programs have been conducted under U.S. Food and Drug Administration guidance, with clinical trials carried out at sites across North America. Matinas pursues strategic collaborations and licensing partnerships to broaden the application of its LNS technology to vaccines, oncology agents and biologics.
Matinas Biopharma completed its initial public offering in 2020 and trades on the New York Stock Exchange under the ticker symbol MTNB. The company’s management team brings together expertise in pharmaceutical R&D, regulatory affairs and commercial development, with the goal of translating its lipid‐delivery platform into safe, effective and convenient therapies for patients worldwide.
